About 10% to 15% of breast cancers are triple-negative. This means they don’t have receptors for the hormones estrogen or progesterone, and don’t have too many HER2 proteins. So, hormonal therapy medicines and medicines that target the HER2 protein aren’t effective against triple-negative breast cancer. Chemotherapy and immunotherapy are commonly used to treat triple-negative disease. But scientists are working diligently to develop new treatments that are more precise and targeted. Triple-negative breast cancer expert Dr. Lisa Carey explains the latest research. Listen to the episode to hear Dr. Carey discuss: the two main areas of research on triple-negative breast cancer what antibody-drug conjugates are and their potential for treating triple-negative disease the benefits of combining antibody-drug conjugates with immunotherapy the features of triple-negative breast cancer that make researchers think a vaccine for it is possible

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related